You are here » Home » Companies » Company Overview » Medicamen Biotech Ltd

Medicamen Biotech Ltd.

BSE: 531146 Sector: Health care
NSE: MEDICAMEQ ISIN Code: INE646B01010
BSE 00:00 | 01 Jul 670.95 0.85
(0.13%)
OPEN

670.60

HIGH

686.55

LOW

667.25

NSE 00:00 | 01 Jul 673.15 3.70
(0.55%)
OPEN

669.45

HIGH

682.80

LOW

660.10

OPEN 670.60
PREVIOUS CLOSE 670.10
VOLUME 406
52-Week high 1023.25
52-Week low 495.55
P/E 55.00
Mkt Cap.(Rs cr) 820
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 670.60
CLOSE 670.10
VOLUME 406
52-Week high 1023.25
52-Week low 495.55
P/E 55.00
Mkt Cap.(Rs cr) 820
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Medicamen Biotech Ltd. (MEDICAMEQ) - Chairman Speech

Company chairman speech

Dear Shareholders

I hope this letter finds you and your beloved ones in good health. It gives me immensepleasure to present to you this year's Annual Report.

The year that taught us not to take anything for granted in life has been unusuallydifferent for everyone. 2020-21 witnessed slowdown in business in the initial months andthe domestic demand remained sluggish due to the Government-imposed nationwide lockdown totame the spread of Covid-19. However in the second half of the year with the easing oflockdown along with a strong economic recovery we have operated with minimum workforceand remained committed to providing high- quality formulations maintaining the highestlevels of compliance.

The Indian economy experienced sluggish growth in 2020-21 like most of the majoreconomies. Consumption and GDP have been on the decline as a result of theGovernment-imposed lockdowns. However the rollout of vaccines increased mobilityprivatisation and the Government's strong financial impetus contributed to the positiveeconomic turnaround.

Oncology is a rapidly evolving therapy field with a plethora of novel technologies inthe development phase that have the potential to drastically alter the treatment paradigm.The oncology market was valued at USD 143 billion in 2019 and is expected to witness aCAGR of 12% between 2020 and 2025. Due to the increasing number of cancer cases diagnosedeach year around the world the segment's valuation is expected to skyrocket. Through ourstate-of-the-art plant in Haridwar we are committed to meeting the growing needs ofpatients in this niche segment. Though our schedule was pushed back due to thepandemic-induced lockdown we have now completed the plant setup and are in the process ofvalidating it.

In the Non-oncology segment we will continue to focus on new generic products tostrengthen our revenues and margins.

Despite the sudden and uncertain challenges we could deliver a spirited performance byrecording a revenue of Rs.11014.65 lakhs in 2020-21. The EBITDA stood at Rs.2033.49 lakhsin 2020-21 whereas PAT was recorded at Rs.1248.66 lakhs.

Quality dependability and innovation remain our core values and they have alwaysprovided us with a distinct competitive advantage. Our R&D team has given birth tosome ground-breaking products and they will be put into production as soon as theOncology plant is operational. The WHO-GMP upgrade of Haridwar Unit 1 is underway and willbe completed by the middle of FY 2021-22. The Bhiwadi (Beta Lactum) unit has beenupgraded. We are now prepared for the EU and Australian markets with our new products. Inaddition a UN audit is scheduled for 2021-22.

I want to express my deepest regards to our valued stakeholders. Your faith and supportfor the management during the pandemic have encouraged us to innovate more for the future.I am thankful to our staff and employees who have demonstrated their adaptability andflexibility during Covid-19. We remain upbeat about our prospects for expansion. Wishingeveryone good health. Do get vaccinated wear masks and stay PREPARED for the times tocome.

Best Wishes

Rahul Bishnoi

Chairman

.